Vimarsana
Biggest News Aggregation in the World

Page 2 - Michael Lampe News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Michael Lampe. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Michael Lampe Today - Breaking & Trending Today

Curaçao Airport Partners launches new branding for our airport - Vimarsana News

Curaçao Airport Partners launches new branding for our airport

A new era, a new name – CUR Curaçao International Airport

Paratek Pharmaceuticals Files Definitive Proxy Statement and Letter to Stockholders in Connection with Acquisition by Gurnet Point Capital and Novo Holdings - Vimarsana News

Paratek Pharmaceuticals Files Definitive Proxy Statement and Letter to Stockholders in Connection with Acquisition by Gurnet Point Capital and Novo Holdings

Transaction Provides Paratek Stockholders with Immediate Value and Liquidity Stockholders to Receive Upfront Cash Payment of $2.15 per Share and a Contingent Value Right of $0.85 per Share on...

Foghorn Therapeutics Announces Participation in Upcoming Investor Conferences - Vimarsana News

Foghorn Therapeutics Announces Participation in Upcoming Investor Conferences

CAMBRIDGE, Mass., June 07, 2023 -- Foghorn® Therapeutics Inc. , a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal... | June 7, 2023

Foghorn Therapeutics Announces FDA Has Lifted Clinical Hold on Phase 1 Study of FHD-286 in Relapsed and/or Refractory AML/MDS Patients - Vimarsana News

Foghorn Therapeutics Announces FDA Has Lifted Clinical Hold on Phase 1 Study of FHD-286 in Relapsed and/or Refractory AML/MDS Patients

- Plan to Initiate a Phase 1 Study of FHD-286 in Combination with Decitabine or Cytarabine in Relapsed and/or Refractory AML Patients in Q3’2023 - Clinical and Pre-Clinical... | June 5, 2023

Foghorn Therapeutics Provides an Update on FHD-609 - Vimarsana News

Foghorn Therapeutics Provides an Update on FHD-609

CAMBRIDGE, Mass., April 24, 2023 -- Foghorn® Therapeutics Inc. , a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal... | June 18, 2023